DCT

1:25-cv-01246

Bayer Healthcare Pharma Inc v. Aurobindo Pharma Ltd

Log In
Key Events
Amended Complaint
complaint Intelligence

I. Executive Summary and Procedural Information

  • Parties & Counsel:

  • Case Identification: 1:25-cv-01246, D. Del., 03/06/2026

  • Venue Allegations: Plaintiff alleges venue is proper because Defendant Zydus Lifesciences is a foreign corporation subject to personal jurisdiction in the district, and because Defendant Zydus Pharmaceuticals intends to market and sell the accused product in Delaware. The complaint also notes that Defendants have stated they will not contest personal jurisdiction or venue in the District of Delaware for the purposes of this action.

  • Core Dispute: Plaintiff alleges that Defendant's Abbreviated New Drug Application (ANDA) to market a generic version of the drug KERENDIA® (finerenone) constitutes an act of infringement of a patent claiming a specific crystalline form of the finerenone active pharmaceutical ingredient.

  • Technical Context: The dispute is in the field of pharmaceutical chemistry, focusing on the specific solid-state form, or polymorph, of an active pharmaceutical ingredient, which can affect a drug's stability, solubility, and bioavailability.

  • Key Procedural History: The patent-in-suit, RE49,826, is a reissue of U.S. Patent No. 10,336,749. The action was initiated under the Hatch-Waxman Act following Zydus's submission of an ANDA with a Paragraph IV certification, alleging that certain claims of the patent-in-suit are invalid and/or will not be infringed by its proposed generic product.

Case Timeline

Date Event
2015-08-21 Earliest Priority Date for RE49,826 Patent
2019-07-02 Issue Date of Original U.S. Patent No. 10,336,749
2021-07-09 FDA Approval of Bayer's KERENDIA® (NDA No. 215341)
2024-02-06 Issue Date of Reissue Patent No. RE49,826
2025-09-05 Bayer receives Zydus's First Paragraph IV Notice Letter
2026-02-13 Bayer receives Zydus's Second Paragraph IV Notice Letter
2026-03-06 Complaint Filing Date

II. Technology and Patent(s)-in-Suit Analysis

U.S. Reissue Patent No. RE49,826 - "Method for the preparation of (4S)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1-6-naphthyridine-3-carboxamide and the purification thereof for use as an active pharmaceutical ingredient"

The Invention Explained

  • Problem Addressed: The patent's background describes prior art methods for synthesizing the finerenone compound as being a "research scale synthesis" that is unsuitable for large-scale industrial production RE'826 Patent, col. 2:4-6 These prior methods allegedly suffered from low overall yield, the need for many intermediate chromatographic purifications, high costs, and safety concerns, making them impractical for commercial manufacturing RE'826 Patent, col. 2:47-58
  • The Patented Solution: The patent discloses a novel and improved process for preparing the finerenone compound that is more efficient and scalable RE'826 Patent, col. 2:61-65 A key aspect of the invention is the isolation of the final compound in a specific, stable crystalline form, designated "polymorph I," which is reproducibly formed and has a defined melting point and other physical characteristics suitable for pharmaceutical formulation RE'826 Patent, col. 13:57-65
  • Technical Importance: Obtaining a specific, stable crystalline polymorph of an active pharmaceutical ingredient is critical in drug development to ensure consistent product quality, bioavailability, and shelf life RE'826 Patent, col. 13:57-62

Key Claims at a Glance

  • The complaint alleges infringement of one or more claims of the RE'826 Patent, and notes that Zydus's Paragraph IV letters addressed claims 14-30 Compl. ¶49 Compl. ¶60 Independent claim 14 is a representative compound claim.
  • Independent Claim 14:
    • A compound of the formula (I) in crystalline form of polymorph I
    • wherein the x-ray diffractogram of the compound exhibits peak maxima of the 2 theta angle at 8.5, 14.1, and 19.0.
  • The complaint does not explicitly reserve the right to assert dependent claims but makes a general allegation of infringement of "one or more claims" Compl. ¶60

III. The Accused Instrumentality

Product Identification

The accused instrumentality is the generic finerenone drug product described in Zydus's ANDA No. 220636 ("Zydus's ANDA Product") Compl. ¶1

Functionality and Market Context

  • Zydus's ANDA Product is a proposed generic version of Bayer's KERENDIA® tablets, intended for the same therapeutic indications Compl. ¶1 The complaint alleges Zydus seeks approval for 10 mg, 20 mg, and 40 mg dosages of finerenone Compl. ¶13 Compl. ¶46 Compl. ¶47
  • The filing of the ANDA itself, seeking approval to market this generic product before the expiration of the RE'826 Patent, constitutes the alleged act of infringement under 35 U.S.C. § 271(e)(2)(A) Compl. ¶58 No probative visual evidence provided in complaint.

IV. Analysis of Infringement Allegations

The complaint does not contain or reference a claim chart exhibit. The infringement allegation is statutory, arising from the submission of ANDA No. 220636 with a Paragraph IV certification Compl. ¶58 The core of this allegation is that Zydus's ANDA Product, if commercially manufactured and sold, would meet the limitations of one or more claims of the RE'826 Patent, including claims to the specific crystalline polymorph I of finerenone. The complaint asserts that Zydus seeks approval to engage in the commercial manufacture, use, or sale of a product claimed in the patent Compl. ¶59

  • Identified Points of Contention:
    • Factual Question: The central dispute will likely be a factual and scientific question: Does the finerenone active ingredient in Zydus's ANDA Product exist in the "crystalline form of polymorph I" as defined by the asserted claims? This determination will rely on analytical evidence, such as X-ray powder diffraction (XRPD) data, comparing Zydus's product to the patent's claims.
    • Scope Questions: A potential dispute may arise over whether meeting only the three X-ray diffraction peaks specified in independent claim 14 is sufficient to fall within the claim's scope, or if "polymorph I" must also meet other characteristics described in the patent's specification.

V. Key Claim Terms for Construction

  • The Term: "crystalline form of polymorph I"
  • Context and Importance: This term is the central limitation of the asserted compound claims. The entire infringement analysis for these claims will depend on whether Zydus's proposed generic product is determined to be this specific polymorph. Practitioners may focus on this term because infringement turns entirely on this scientific characterization.
  • Intrinsic Evidence for Interpretation:
    • Evidence for a Broader Interpretation: The plain language of claim 14 defines the polymorph by requiring the presence of three specific peak maxima in its x-ray diffractogram (8.5, 14.1, and 19.0) RE'826 Patent, claim 14 A party could argue that this is the complete and sufficient definition for the purpose of the claim.
    • Evidence for a Narrower Interpretation: The specification provides a more extensive characterization of polymorph I, including a much longer list of twenty-seven x-ray diffractogram peaks, specific IR spectrum band maxima, Raman spectrum band maxima, and a defined melting point RE'826 Patent, col. 14:45-68 RE'826 Patent, col. 15:14-20 RE'826 Patent, col. 42:20-65 A party might argue that to be "polymorph I," a compound must exhibit these additional characteristics, not just the three peaks recited in the claim.

VI. Other Allegations

  • Indirect Infringement: The complaint alleges that Zydus knows and intends for healthcare professionals and patients to use its ANDA Product in accordance with the product's labeling, which will induce and/or contribute to infringement of the RE'826 Patent Compl. ¶69
  • Willful Infringement: The complaint alleges that Zydus "has acted with full knowledge of the RE'826 Patent" Compl. ¶62 This knowledge is evidenced by Zydus's submission of Paragraph IV certifications specifically directed to the patent-in-suit Compl. ¶45 Compl. ¶47

VII. Analyst's Conclusion: Key Questions for the Case

  • A central issue will be one of scientific fact: Does the active pharmaceutical ingredient in Zydus's ANDA product exhibit the specific atomic arrangement that defines "crystalline form of polymorph I" as claimed in the RE'826 patent? The case will likely involve a battle of competing analytical data and expert testimony on techniques like X-ray crystallography.
  • A second critical issue will be validity: As raised in its Paragraph IV letters, can Zydus demonstrate by clear and convincing evidence that the claims covering polymorph I are invalid, for instance, as obvious over the prior art? This could involve arguing that producing this specific crystalline form was an inherent or predictable outcome of developing a scalable manufacturing process for a known compound.